{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Achieved CR or PR"},{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}],"title":"Did not Achieve CR or PR"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"To assess the complete response (CR) + partial response (PR) rate (as defined by the 2015 MDS/MPN-IWG criteria) with cobimetinib treatment in CMML.\n\nThis outcome measure will report the count of patients achieving complete response complete response (CR) or partial response (PR) while on the study.","groups":[{"description":"Patients treated with hypomethylating agent (HMA) refractory chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG000","title":"HMA Refractory"},{"description":"Patients with newly diagnosed chronic myelomonocytic leukemia (CMML; 2022 WHO classification) with RAS pathway activation.\n\nExperimental: Treatment: All Patients Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken once daily for 21 consecutive days (Days 1 to 21-treatment period); followed by a 7-day break (Days 22 to 28-treatment break). Each subsequent cobimetinib treatment cycle should start after a 7-day treatment break has elapsed.","id":"OG001","title":"Newly Diagnosed"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From the start of study treatment, until the last disease assessment, up to 20 months","title":"Count of Patients Achieving Complete Response Complete Response (CR) or Partial Response (PR)","type":"SECONDARY","unitOfMeasure":"Participants"}